Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Pivmecillinam→

Pivmecillinam Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
32886-97-8
Molecular formula
C21H33N3O5S
Molecular weight
439.57 g/mol
Drug class
Amidinopenicillin beta-lactam antibacterialoral prodrug of mecillinam
Mechanism of action
Pivmecillinam is rapidly hydrolysed to mecillinam, which inhibits bacterial cell-wall biosynthesis by preferentially binding penicillin-binding protein 2 (PBP-2) in Gram-negative bacteria.
Indications / reported uses
  • Treatment of uncomplicated urinary tract infections in adult women caused by susceptible Escherichia coli, Proteus mirabilis or Staphylococcus saprophyticus, under the current product label.

Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=440a5f17-ab11-0fc8-e063-6394a90a58e9&type=display · https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-uncomplicated-urinary-tract-infections · DailyMed

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Pivmecillinam Environmental Risk Assessment (ERA) (the Pivmecillinam ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.